Eleni-Rosalina Andrinopoulou

List of Publications by Year
in descending order

90 papers	4,451 citations	109321 35 h-index	118850 62 g-index
93 all docs	93 docs citations	93 times ranked	6433 citing authors

#	Article	IF	Citations
1	Cox regression model under dependent truncation. Biometrics, 2022, 78, 460-473.	1.4	5
2	Signature laminar distributions of pathology in frontotemporal lobar degeneration. Acta Neuropathologica, 2022, 143, 363-382.	7.7	12
3	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1495.	12.8	11
4	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	12.8	34
5	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathologica, 2022, 143, 15-31.	7.7	29
6	Genetic and Neurophysiological Biomarkers of Neuroplasticity Inform Post-Stroke Language Recovery. Neurorehabilitation and Neural Repair, 2022, 36, 371-380.	2.9	0
7	Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimerâ€™s Disease to Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 1155-1167.	2.8	9
8	Plasma <scp>MIA</scp>, <scp>CRP</scp>, and Albumin Predict Cognitive Decline in Parkinson's Disease. Annals of Neurology, 2022, 92, 255-269.	5.3	7
9	Self- and Partner-Reported Subjective Memory Complaints: Association with Objective Cognitive Impairment and Risk of Decline. Journal of Alzheimer's Disease Reports, 2022, 6, 411-430.	2.2	4
10	A Bayesian joint model for zeroâ€inflated integers and leftâ€truncated event times with a timeâ€varying association: Applications to senior health care. Statistics in Medicine, 2021, 40, 147-166.	1.6	3
11	Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau. NeuroImage: Clinical, 2021, 31, 102717.	2.7	6
12	Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology. Acta Neuropathologica Communications, 2021, 9, 30.	5.2	22
13	Reflection on modern methods: Dynamic prediction using joint models of longitudinal and time-to-event data. International Journal of Epidemiology, 2021, 50, 1731-1743.	1.9	19
14	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 737-745.	2.8	5
15	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. Movement Disorders, 2021, 36, 2945-2950.	3.9	63
16	Common genetic variation is associated with longitudinal decline and network features in behavioral variant frontotemporal degeneration. Neurobiology of Aging, 2021, 108, 16-23.	3.1	2
17	Putative Antidepressant Effect of Chamomile (Matricaria chamomilla L.) Oral Extract in Subjects with Comorbid Generalized Anxiety Disorder and Depression. Journal of Alternative and Complementary Medicine, 2020, 26, 815-821.	2.1	33
18	Cognitive and neurodegenerative profile differences between â€œmismatch MCIâ€•(A+Tâ€Nâ€+ MCI) And â€œprodromal ADâ€•(A+T+N+ MCI) increase with time. Alzheimer's and Dementia, 2020, 16, e046030.	0.8	0

#	Article	IF	Citations
19	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	7.7	210
20	Meta-Analysis of Several Epidemic Characteristics of COVID-19. Journal of Data Science, 2020, 18, 536-549.	0.9	11
21	New York City COVID-19 resident physician exposure during exponential phase of pandemic. Journal of Clinical Investigation, 2020, 130, 4726-4733.	8.2	72
22	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. Annals of Neurology, 2019, 85, 259-271.	5.3	88
23	Empiric Methods to Account for Pre-analytical Variability in Digital Histopathology in Frontotemporal Lobar Degeneration. Frontiers in Neuroscience, 2019, 13, 682.	2.8	13
24	Genetic predictors of survival in behavioral variant frontotemporal degeneration. Neurology, 2019, 93, e1707-e1714.	1.1	11
25	Bias induced by ignoring double truncation inherent in autopsyâ€confirmed survival studies of neurodegenerative diseases. Statistics in Medicine, 2019, 38, 3599-3613.	1.6	7
26	Longitudinal progression of grey matter atrophy in non-amnestic Alzheimerâ€™s disease. Brain, 2019, 142, 1701-1722.	7.6	37
27	Divergent patterns of TDPâ€43 and tau pathologies in primary progressive aphasia. Annals of Neurology, 2019, 85, 630-643.	5.3	40
28	TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. Annals of Neurology, 2019, 85, 801-811.	5.3	52
29	Older Adult Normative Data for the Sniffinâ€™ Sticks Odor Identification Test. Archives of Clinical Neuropsychology, 2019, 34, 254-258.	0.5	5
30	Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2019, 69, 119-124.	2.2	26
31	Occupational attainment influences longitudinal decline in behavioral variant frontotemporal degeneration. Brain Imaging and Behavior, 2019, 13, 293-301.	2.1	18
32	CSF tau and Î²-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology, 2018, 90, e1038-e1046.	1.1	68
33	The Kaplanâ€“Meier method for estimating and comparing proportions in a randomized controlled trial with dropouts. Biostatistics and Epidemiology, 2018, 2, 23-33.	0.4	9
34	Differential Î±-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. Acta Neuropathologica, 2018, 135, 855-875.	7.7	94
35	Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. Brain, 2018, 141, 288-301.	7.6	56
36	Cox Regression Model with Doubly Truncated Data. Biometrics, 2018, 74, 725-733.	1.4	24

#	Article	IF	Citations
37	Improved Dynamic Predictions from Joint Models of Longitudinal and Survival Data with Time-varying Effects Using P-splines. Biometrics, 2018, 74, 685-693.	1.4	39
38	APOE, thought disorder, and SPAREâ€AD predict cognitive decline in established Parkinson's disease. Movement Disorders, 2018, 33, 289-297.	3.9	35
39	Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease. Neurobiology of Aging, 2018, 63, 75-87.	3.1	61
40	ICâ€06â€03: DISTINCT LONGITUDINAL CORTICAL ATROPHY IN NONâ€AMNESTIC COMPARED TO AMNESTIC ALZHEIMER'S DISEASE SUGGESTS DIFFERENT PATTERNS OF SPREADING PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P12.	0.8	0
41	P3â€406: DISTINCT LONGITUDINAL CORTICAL ATROPHY IN NONâ€AMNESTIC COMPARED TO AMNESTIC ALZHEIMER'S DISEASE SUGGESTS DIFFERENT PATTERNS OF SPREADING PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P1259.	0.8	0
42	Evaluation of Linguistic Markers of Word-Finding Difficulty and Cognition in Parkinson's Disease. Journal of Speech, Language, and Hearing Research, 2018, 61, 1691-1699.	1.6	19
43	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain, 2018, 141, 2181-2193.	7.6	448
44	Non-Alzheimerâ€™s contributions to dementia and cognitive resilience in The 90+ Study. Acta Neuropathologica, 2018, 136, 377-388.	7.7	112
45	Combined dynamic predictions using joint models of two longitudinal outcomes and competing risk data. Statistical Methods in Medical Research, 2017, 26, 1787-1801.	1.5	27
46	Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG). Journal of Neuropathology and Experimental Neurology, 2017, 76, 605-619.	1.7	38
47	Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2017, 76, 270-288.	1.7	98
48	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurology, The, 2017, 16, 55-65.	10.2	394
49	Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study. Movement Disorders, 2017, 32, 1636-1640.	3.9	18
50	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Annals of Neurology, 2017, 82, 247-258.	5.3	51
51	Statins and Cognition in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2017, 7, 661-667.	2.8	13
52	Regional brain amyloid-Î² accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS ONE, 2017, 12, e0177924.	2.5	33
53	Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration. Acta Neuropathologica Communications, 2017, 5, 68.	5.2	34
54	Development and Validation of the Parkinsonâ€™s Disease Medication Beliefs Scale (PD-Rx). Journal of Parkinson's Disease, 2016, 6, 383-392.	2.8	7

#	Article	IF	Citations
55	Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors. Scientific Reports, 2016, 5, 18286.	3.3	37
56	Bayesian shrinkage approach for a joint model of longitudinal and survival outcomes assuming different association structures. Statistics in Medicine, 2016, 35, 4813-4823.	1.6	36
57	Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine, 2016, 23, 1735-1742.	5.3	88
58	Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 463-470.	2.6	1
59	Research consent capacity varies with executive function and memory in Parkinson's disease. Movement Disorders, 2016, 31, 414-417.	3.9	12
60	Amyloidâ€Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. Movement Disorders Clinical Practice, 2016, 3, 367-375.	1.5	28
61	Semi-Automated Digital Image Analysis of Pickâ€™s Disease and TDP-43 Proteinopathy. Journal of Histochemistry and Cytochemistry, 2016, 64, 54-66.	2.5	43
62	Olfactory impairment predicts cognitive decline in early Parkinson's disease. Parkinsonism and Related Disorders, 2016, 25, 45-51.	2.2	97
63	CHoosing Options for Insomnia in Cancer Effectively (CHOICE): Design of a patient centered comparative effectiveness trial of acupuncture and cognitive behavior therapy for insomnia. Contemporary Clinical Trials, 2016, 47, 349-355.	1.8	23
64	Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 864-870.	1.9	105
65	An Alzheimerâ€™s Disease-Derived Biomarker Signature Identifies Parkinsonâ€™s Disease Patients with Dementia. PLoS ONE, 2016, 11, e0147319.	2.5	25
66	Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 987-994.	2.6	67
67	Assessing treatment effects with surrogate survival outcomes using an internal validation subsample. Clinical Trials, 2015, 12, 333-341.	1.6	7
68	Rivastigmine for mild cognitive impairment in Parkinson disease: A placeboâ€controlled study. Movement Disorders, 2015, 30, 912-918.	3.9	91
69	Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients. Movement Disorders, 2015, 30, 1648-1656.	3.9	66
70	Nonparametric discrete survival function estimation with uncertain endpoints using an internal validation subsample. Biometrics, 2015, 71, 772-781.	1.4	3
71	Long-Term Chamomile Therapy of Generalized Anxiety Disorder: A Study Protocol for a Randomized, Double-Blind, Placebo- Controlled Trial. Journal of Clinical Trials, 2015, 04, .	0.1	12
72	Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Phytomedicine, 2015, 22, 394-399.	5.3	85

#	Article	IF	Citations
73	Occupational attainment influences survival in autopsy-confirmed frontotemporal degeneration. Neurology, 2015, 84, 2070-2075.	1.1	30
74	Identifying amyloid pathologyâ€“related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 339-348.	2.4	35
75	Dynamic prediction of outcome for patients with severe aortic stenosis: application of joint models for longitudinal and time-to-event data. BMC Cardiovascular Disorders, 2015, 15, 28.	1.7	24
76	Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. Journal of Clinical Oncology, 2015, 33, 3615-3620.	1.6	95
77	Longitudinal study of normal cognition in Parkinson disease. Neurology, 2015, 85, 1276-1282.	1.1	197
78	Rhodiola Rosea Therapy for Major Depressive Disorder: A Study Protocol for a Randomized, Double-Blind, Placebo- Controlled Trial. Journal of Clinical Trials, 2014, 04, 170.	0.1	11
79	Expectancy in Real and Sham Electroacupuncture: Does Believing Make It So?. Journal of the National Cancer Institute Monographs, 2014, 2014, 302-307.	2.1	29
80	Joint modeling of two longitudinal outcomes and competing risk data. Statistics in Medicine, 2014, 33, 3167-3178.	1.6	55
81	Naltrexone for impulse control disorders in Parkinson disease. Neurology, 2014, 83, 826-833.	1.1	74
82	A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. European Journal of Cancer, 2014, 50, 267-276.	2.8	97
83	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimer's and Dementia, 2014, 10, 477.	0.8	167
84	Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. NeuroImage: Clinical, 2014, 4, 164-173.	2.7	112
85	Adjustment for measurement error in evaluating diagnostic biomarkers by using an internal reliability sample. Statistics in Medicine, 2013, 32, 4709-4725.	1.6	7
86	A Pragmatic Evaluation of the National Cancer Institute Physician Data Query (PDQ)Â®-Based Brief Counseling on Cancer-Related Fatigue among Patients Undergoing Radiation Therapy. Journal of Palliative Care & Medicine, 2012, 02, .	0.1	2
87	An Introduction to Mixed Models and Joint Modeling: Analysis of Valve Function Over Time. Annals of Thoracic Surgery, 2012, 93, 1765-1772.	1.3	48
88	Building an integrated neurodegenerative disease database at an academic health center. Alzheimer's and Dementia, 2011, 7, e84-93.	0.8	63
89	Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimerâ€™s disease. Journal of the International Neuropsychological Society, 2010, 16, 278-286.	1.8	21
90	Measurement error reduction using weighted average method for repeated measurements from heterogeneous instruments. Environmetrics, 2001, 12, 785-790.	1.4	2